| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Fosinopril Sodium (also known as SQ28555), the ester prodrug offosinoprilat, is a potent angiotensin-converting enzyme (ACE) inhibitor that is used for the treatment of hypertension and some types of chronic heart failure. Fosinopril Sodium is a phosphinic acid-containing ACEinhibitor that is effective in the treatment of hypertension. Fosinoprilbinds to the active site of ACE via targeting the zinc ions with its phosphinic acid moiety.
| ln Vitro |
Co-sedimentation of liposomes and recombinant LPLA2 is partially inhibited by fosinopril (0, 1, 10, 33, 100 μM; 30 min) [1]. The soluble esterase activity of LPLA2 is not inhibited by fosinopril (250 nM) [1]. With a Ki value of 1.675 μM, fosinopril (0.372, 0.744, 1.116 μM) inhibits ACE activity in a non-competitive manner [2].
|
|---|---|
| ln Vivo |
By decreasing the levels of lactate dehydrogenase (LDH) and creatine kinase (CK), fosinopril (oral; 4.67 mg/kg; 4 weeks) counteracts cardiac dysfunction and structural alterations [3]. In rat models of acute myocardial infarction, fosinopril (oral; 4.67 mg/kg; 4 weeks) reduces the expression of cleaved-caspase 3 and cardiomyocyte apoptosis.
|
| Animal Protocol |
Animal/Disease Models: Acute myocardial infarction (AMI) rat model after heart failure (SPF grade SD (SD (Sprague-Dawley)) rat, 265±15g) [3]
Doses: 4.67mg/kg Route of Administration: oral; 4-week Experimental Results: Combats cardiac dysfunction and structural changes and inhibits apoptosis. |
| References |
|
| Additional Infomation |
Fosinopril sodium is the sodium salt of fosinopril. It is used for the treatment of hypertension and heart failure. A pro-drug, its phosphinate ester group is hydrolysed in vivo to give the corresponding phosphininc acid, fosinoprilat, which is the active metabolite. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, a prodrug and an antihypertensive agent. It contains a fosinopril(1-).
Fosinopril Sodium is the sodium salt of fosinopril, a phosphinic acid-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Fosinopril sodium is an ester prodrug that is hydrolysed by esterases to its active metabolite fosinoprilat. Fosinoprilat specifically and competitively inhibits angiotensin-converting enzyme thereby decreasing the formation of the potent vasoconstrictor angiotensin II, resulting in diminished vasopressor activity. In addition, angiotensin II-mediated aldosterone secretion by adrenal cortex is decreased, which results in a decrease of sodium retention and an increase of serum potassium. (NCI05) A phosphinic acid-containing angiotensin-converting enzyme inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat. See also: Fosinopril (has active moiety); Fosinoprilat (has active moiety); Fosinopril sodium; hydrochlorothiazide (component of). |
| Molecular Formula |
C30H45NO7P.NA
|
|---|---|
| Molecular Weight |
585.64
|
| Exact Mass |
563.301
|
| CAS # |
88889-14-9
|
| Related CAS # |
Fosinopril;98048-97-6
|
| PubChem CID |
23681451
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
705.7±70.0 °C at 760 mmHg
|
| Melting Point |
196-198ºC
|
| Flash Point |
380.6±35.7 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.532
|
| LogP |
6.09
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
40
|
| Complexity |
857
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)[O-])C3CCCCC3.[Na+]
|
| InChi Key |
TVTJZMHAIQQZTL-HREVRLCXSA-M
|
| InChi Code |
InChI=1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30?,39?;/m1./s1
|
| Chemical Name |
sodium;(2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylate
|
| Synonyms |
SQ-28,555;SQ 28,555; SQ 28555; SQ-28,555; SQ-28555; SQ28,555; SQ28555; Monopril; Staril; Dynacil; Fosinil; Tenso Stop; Tensocardil; Sodium, Fosinopril; Staril;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO:<1 mg/mL
Water:117 mg/mL (199.8 mM)
Ethanol:4 mg/mL (6.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 9.09 mg/mL (15.52 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7075 mL | 8.5377 mL | 17.0753 mL | |
| 5 mM | 0.3415 mL | 1.7075 mL | 3.4151 mL | |
| 10 mM | 0.1708 mL | 0.8538 mL | 1.7075 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA